Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Comparative Study of Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Patients

NCT01885013 is registered in ClinicalTrials.gov with Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS as lead sponsor.

NCT NCT01885013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01885013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Comparative Study of Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Patients
Lead sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
May 31, 2015
Enrollment
126 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

human epidermal growth factor 2 negative carcinoma of breast